Skip to content
DataLookout
Menu

NCT07215910

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 152 → 177 locations
  2. Notable Eligibility criteria expanded, about 41 words
    • Trial sites expanded: 121 → 152 locations
    • Secondary endpoints: details revised at 16 of 16 entries
    • Study description revised
  3. Minor Trial sites expanded: 97 → 121 locations
    • Start date changed from estimate of Jul 20, 2026 to Jun 24, 2026
    v5
  4. Minor Trial sites expanded: 82 → 97 locationsv4
  5. Minor Trial sites expanded: 75 → 82 locationsv3
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Oct 20, 2025 to Jul 20, 2026
    • Study sites: 0 to 75
    v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression free survival (PFS) by blinded independent central review (BICR)
Timeframe: assessed up to 10 years

Secondary (16)

Progression free survival (PFS) by local review
Incidence of adverse events (AEs)
Overall survival (OS)
Objective response rate (ORR) by blinded independent central review (BICR)
Complete response (CR) + partial response (PR) rate by blinded independent central review (BICR)
Show 11 moreShow less
Time to response by blinded independent central review (BICR)
Time to complete response (CR) + partial response (PR) by blinded independent central review (BICR)
Duration of response by blinded independent central review (BICR)
Duration of Complete response (CR) + partial response (PR) by blinded independent central review (BICR)
Objective response rate (ORR) by local review
Complete response (CR) + partial response (PR) rate by local review
Time to response by local review
Time to complete response (CR) + partial response (PR) by local review
Duration of response by local review
Duration of Complete response (CR) + partial response (PR) by local review
Time to next therapeutic intervention

Arms and interventions

Arm I (temozolomide, placebo)Placebo comparator

Patients receive IMRT/VMAT or PBS or IMPT QD on Monday-Friday for 33 fractions. Starting 4 weeks after radiotherapy, patients receive temozolomide PO QD on days 1-5 and placebo PO QD on days 1-28 of each cycle. Cycles of combination treatment repeat every 28 days for up to 12 months and placebo alone repeats every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI throughout the study.

Arm II (temozolomide, vorasidenib)Experimental

Patients receive IMRT/VMAT or PBS or IMPT QD on Monday-Friday for 33 fractions. Starting 4 weeks after radiotherapy, patients receive temozolomide PO QD on days 1-5 and vorasidenib PO QD on days 1-28 of each cycle. Cycles of combination treatment repeat every 28 days for up to 12 months and vorasidenib alone repeats every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI throughout the study.

Radiation: Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning

Procedures: Intensity-Modulated Proton Therapy, Biospecimen Collection, Magnetic Resonance Imaging

Drugs: Temozolomide, Vorasidenib, Placebo Administration

Other: Questionnaire Administration

Sites

177 sites in 1 country